Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...
WebMD17d
Treating Growth Hormone Deficiency With Skytrofa
Clinical guidelines recommend human growth hormone products for children with GHD. How Long Until I See the Effects of Skytrofa? It can take several months to see the effects of Skytrofa.
HealthDay on MSN10d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...
Labroots25d
FDA approval of new drug for hormone positive breast cancer
On January 17, 2025, the Food and Drug Administration (FDA ... This approval marks a significant advancement in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor ...